Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IsoSAFE: Inhaled Isoflurane Sedation in Severe TBI
NCT06311604Recruiting
- Sponsor
- CHU Grenoble Alpes
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Open-label, single-arm trial of isoflurane in traumatic brain injury (TBI), sponsored by CHU Grenoble Alpes. Primary endpoint: Safety of sedation with 0.7 MAC of inhaled isoflurane in terms of intracranial pressure at 36 hours. Started Jun 2024; status: recruiting.
02
Drugs
isoflurane
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT06311604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06311604.